New, long-acting clotting factors are on their way, with Biogen Idec's hemophilia B drug Alprolix first in line. The new treatments promise to prevent bleeding for up to two weeks, and that means today's injections will have to find a way to compete.
The big biotech worked a deal with Eisai, offering to cover half of the research and development costs of a pair of mid-stage Alzheimer's therapies and adding an unspecified package of milestones and an upfront in exchange for half the potential profits.
Carlsbad, CA's Isis Pharmaceuticals is touting mid-stage results for its in-development spinal muscular atrophy treatment, setting its sights on a Phase III study and sending its shares up about 15%.
Biogen Idec's hot-selling multiple sclerosis drug Tecfidera has to win reimbursement in individual European countries where governments have gotten stingy about parting with healthcare dollars. A decision Thursday by U.K. price watchdog NICE is an indication of the cost hurdles to be faced.
Biogen Idec chairman William Young is taking his last lap at the fast-growing Boston biotech. Young plans to step down from the board in May, when he'll be relieved by Stelios Papadopoulos, the cofounder of Exelixis.
Bayer has posted a fresh set of positive data on its hemophilia therapy BAY94-9027. But with a timeline that doesn't anticipate a regulatory filing until next year, at least one prominent analyst says that Biogen Idec still commands a lead in their race to the market.
Isis and partner Biogen Idec have kicked off a Phase II study of a spinal muscular atrophy treatment, part of the pair's $300 million alliance to advance antisense treatments.
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Biogen Idec's fast-selling new multiple sclerosis drug won approval in a broad new market: Europe. After sewing up its Tecfidera intellectual property rights there last year, Biogen can now roll out the drug for first-line MS treatment across the continent.
UCB could have a tiger by the tail in Asia, with regional rights to market top-selling Biogen Idec products. The deal includes Biogen's brand-new multiple sclerosis treatment Tecfidera, which is roaring toward blockbuster sales in the U.S. less than a year after launch.